Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)

Clinical trial NCT03768505 · TERMINATED

Trial details

NCT number: NCT03768505
Sponsor: MEI Pharma, Inc.
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Follicular Lymphoma (FL)Non Hodgkin Lymphoma Marginal Zone Lymphoma

Start date: 2019-06-25
Primary completion: 2023-03-24
Enrollment: 169

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.